ABSTRACT
Down syndrome (DS) is associated with many dermatological conditions, including hidradenitis suppurativa, folliculitis, and alopecia areata. Despite the high incidence of skin conditions in this population, there are no quality of life (QoL) studies in the dermatology literature focused on patients with DS or their caregivers. The frequently used QoL assessment tool, the Dermatology Life Quality Index (DLQI), has yet to be studied in this population. This study addresses these disparities by capturing how various skin conditions affect the QoL of people with DS and their caregivers and assessing the utility of the DLQI.
Subject(s)
Caregivers , Down Syndrome , Quality of Life , Skin Diseases , Humans , Caregivers/psychology , Male , Female , Child , Adolescent , Adult , Skin Diseases/psychology , Surveys and Questionnaires , Young Adult , Child, Preschool , Middle AgedABSTRACT
Metopic ridge (MeR) is a midline osseous forehead prominence resulting from physiologic closure of the underlying metopic suture. This mass-like ridge can be mistaken for serious conditions such as a craniosynostosis or vascular anomaly, prompting concern and workup. We reviewed patients presenting for a forehead mass to Vascular Anomalies and Dermatology clinics and diagnosed with MeR to increase familiarity with this finding and to encourage MeR in the differential diagnosis of pediatric midline forehead masses.
Subject(s)
Craniosynostoses , Dermatology , Vascular Malformations , Humans , Child , Infant , Craniosynostoses/diagnosis , Craniosynostoses/surgery , Cranial Sutures , Vascular Malformations/diagnosis , Diagnosis, DifferentialABSTRACT
Down syndrome (DS) is the most common chromosomal condition and affects many organs including the skin. Dermatologists are an integral part of the DS care team. This is a review of both common and rare dermatologic conditions in DS. We provide practical strategies for a successful dermatology interview and examination. We explore the downstream effects of trisomy of chromosome 21, in particular on the immune system, and how these insights may enhance our pathophysiologic understanding of their cutaneous conditions.
Subject(s)
Down Syndrome , Skin Diseases , Down Syndrome/complications , Humans , Skin , Skin Diseases/diagnosisABSTRACT
BACKGROUND: Current literature addressing dermatologic conditions associated with Down syndrome is limited, with emphasis on rare skin conditions and lack of consensus on the incidence of more common disorders. OBJECTIVE: We sought to evaluate dermatologic conditions in patients with Down syndrome diagnosed and managed by dermatologists. METHODS: This was a retrospective analysis of 101 pediatric and adult patients with Down syndrome seen by the University of Massachusetts Dermatology Department between 2008 and 2018. RESULTS: Folliculitis was the most common diagnosis overall (30.7%), followed by seborrheic dermatitis (26.7%) and hidradenitis suppurativa (22.8%). Eczematous dermatitis, alopecia areata, and xerosis were the most common diagnoses observed in children aged 0-12 years; hidradenitis suppurativa, folliculitis, and seborrheic dermatitis in adolescents aged 13-17 years; and folliculitis, seborrheic dermatitis, and xerosis in adults 18 years and older. Other notable diagnoses present overall included onychomycosis (9.9%) and psoriasis (8.9%). Malignant cutaneous tumors were present in two patients, specifically basal cell carcinoma and malignant melanoma in situ. LIMITATIONS: This was a retrospective, single-institution study. CONCLUSION: Dermatologic conditions in patients with Down syndrome vary by age but are most often adnexal and eczematous disorders. Trisomy of chromosome 21 and the resulting downstream effects, specifically on the immune system, may account for these findings.
Subject(s)
Down Syndrome , Hidradenitis Suppurativa , Psoriasis , Skin Diseases , Skin Neoplasms , Adolescent , Adult , Child , Child, Preschool , Down Syndrome/complications , Down Syndrome/epidemiology , Humans , Infant , Infant, Newborn , Psoriasis/complications , Psoriasis/diagnosis , Psoriasis/epidemiology , Retrospective Studies , Skin Diseases/diagnosis , Skin Diseases/epidemiology , Skin Neoplasms/diagnosis , Skin Neoplasms/epidemiologySubject(s)
Hemangioma, Capillary , Timolol , Administration, Topical , Adrenergic beta-Antagonists , Hemangioma , Humans , Infant , Skin Neoplasms , Treatment OutcomeABSTRACT
Althouygh Menkes disease has well-recognized neurologic, developmental, and cutaneous features, the initial presentation may resemble child abuse. We describe a 5-month-old boy with multiple fractures indicative of nonaccidental trauma who was ultimately diagnosed with Menkes disease. Copper deficiency leads to connective tissue abnormalities and may result in subdural hematomas, wormian bones, cervical spine defects, rib fractures, and spurring of the long bone metaphyses. Several of these findings, including fractures and subdural hematomas, may be misinterpreted as child abuse.
Subject(s)
Child Abuse/diagnosis , Fractures, Multiple/diagnostic imaging , Infant, Premature , Menkes Kinky Hair Syndrome/diagnosis , Diagnosis, Differential , Emergency Service, Hospital , Follow-Up Studies , Fractures, Multiple/diagnosis , Humans , Infant , Male , Menkes Kinky Hair Syndrome/diagnostic imaging , Radiography/methods , Risk AssessmentABSTRACT
Phototherapy can be a safe and effective treatment for various skin diseases in children. Special considerations governing the use of this treatment modality in pediatric populations include patient, family, and facility-based factors that are oriented around heightened concerns with regard to safety and tolerability of treatment. Although phototherapy has been found to be effective in a wide range of dermatologic conditions affecting pediatric populations, including psoriasis, atopic dermatitis, pityriasis lichenoides, cutaneous T-cell lymphoma, and vitiligo, there is need for additional research on other conditions in which phototherapy has shown promise.
Subject(s)
Patient Selection , Skin Diseases/radiotherapy , Ultraviolet Therapy , Adolescent , Child , Child, Preschool , Dermatitis, Atopic/radiotherapy , Humans , Infant , Infant, Newborn , Lymphoma, T-Cell, Cutaneous/radiotherapy , Pityriasis Lichenoides/radiotherapy , Psoriasis/radiotherapy , Ultraviolet Therapy/adverse effects , Ultraviolet Therapy/methods , Vitiligo/radiotherapyABSTRACT
PURPOSE OF REVIEW: Vitiligo and alopecia areata are common, disfiguring skin diseases. Treatment options are limited and include nontargeted approaches, such as corticosteroids, topical calcineurin inhibitors, narrow band ultraviolet B phototherapy, and other immune-modifying agents. The purpose of this article is to review shared, novel mechanisms between vitiligo and alopecia areata, as well as discuss how they inform the development of future targeted treatments. RECENT FINDINGS: Vitiligo and alopecia areata are both autoimmune diseases, and striking similarities in pathogenesis have been identified at the level of both the innate and adaptive immune system. Increased reactive oxygen species and high cellular stress level have been suggested as the initiating trigger of the innate immune system in both diseases, and genome-wide association studies have implicated risk alleles that influence both innate and adaptive immunity. Most importantly, mechanistic studies in mouse models of vitiligo and alopecia areata have specifically implicated an interferon (IFN)γ-driven immune response, including IFNγ, IFNγ-induced chemokines, and cytotoxic CD8 T cells as the main drivers of disease pathogenesis. These recent discoveries may reveal an effective strategy to develop new treatments, and several proof-of-concept clinical studies support this hypothesis. SUMMARY: The identification of IFNγ-driven immune signaling pathways has enabled discoveries of potential new treatments for vitiligo and alopecia areata, and supports initiation of larger clinical trials.
Subject(s)
Alopecia Areata/immunology , Autoimmunity , Immunosuppressive Agents/therapeutic use , Immunotherapy/methods , Vitiligo/immunology , Adaptive Immunity/genetics , Adaptive Immunity/immunology , Alopecia Areata/drug therapy , Alopecia Areata/genetics , Genome-Wide Association Study , Humans , Immunity, Innate/genetics , Immunity, Innate/immunology , Interferon-gamma/immunology , Reactive Oxygen Species/immunology , Signal Transduction/drug effects , Vitiligo/drug therapy , Vitiligo/geneticsABSTRACT
Capillary malformation (CM) can be a "red flag" for several syndromic vascular anomalies. We identified a subset of patients with diffuse CM and fetal pleural effusion and documented the type of CM, the etiology of the pleural effusion, the potential syndromic diagnosis, and outcome. Patients with a history of CM and fetal pleural effusion were identified by searching the database of patients evaluated at the Vascular Anomalies Center at Boston Children's Hospital. Standardized patient interviews and a retrospective review of records, photographs, and imaging studies were conducted. Five patients had diffuse CM and fetal pleural effusion. Two patients had macrocephaly-CM (M-CM), one had features of M-CM and CLOVES (congenital lipomatous overgrowth, vascular malformations, epidermal nevi, and spinal/skeletal anomalies and/or scoliosis), and one had diffuse CM with overgrowth. The pleural fluid was chylous in four patients. One patient had thoracic lymphatic malformation. Recurrent effusion occurred in one patient coincident with pneumonia at age 11 years. Four patients had a history of reactive airway disease and episodic pulmonary infections. The diagnosis of vascular anomaly-overgrowth syndromes, particularly M-CM, should be considered in neonates with fetal pleural effusion.
Subject(s)
Capillaries/abnormalities , Pleural Effusion/complications , Vascular Malformations/etiology , Adolescent , Child , Child, Preschool , Female , Humans , Male , Megalencephaly/diagnosis , Pleural Effusion/diagnosis , Vascular Malformations/diagnosisABSTRACT
Hutchinson-Gilford progeria syndrome (HGPS) is a rare, uniformly fatal, premature aging disease with distinct dermatologic features. We sought to identify and describe the initial skin and hair findings as potential diagnostic signs of the disease. We performed a chart review of the structured initial intake histories of 39 individuals with HGPS enrolled in clinical trials from 2007 to 2010 at Boston Children's Hospital, limited to cutaneous history from birth to 24 months. Medical photographs were provided through the clinical trials and the Progeria Research Foundation Medical and Research Database at Brown University Center for Gerontology and Healthcare Research. All 39 patients reported skin and hair abnormalities within the first 24 months of life. Pathologies included sclerodermoid change, prominent superficial veins, dyspigmentation, and alopecia. The mean age of presentation for each finding was <12 months. The most frequently reported skin feature was sclerodermoid change, which commonly involved the abdomen and bilateral lower extremities. Prominent superficial vasculature manifested as circumoral cyanosis and pronounced veins on the scalp and body. Hypo- and hyperpigmentation were observed over areas of sclerodermoid change. Scalp alopecia progressed in a distinct pattern, with preservation of the hair over the midscalp and vertex areas for the longest period of time. HGPS has distinct cutaneous manifestations during the first 2 years of life that may be the first signs of disease. Awareness of these findings could expedite diagnosis.
Subject(s)
Progeria/pathology , Skin/pathology , Boston , Child , Child, Preschool , Disease Progression , Female , Humans , Infant , MaleABSTRACT
Although it is known that hematopoietic stem cell transplantation (HSCT) survivors are at risk of nonmelanoma skin cancer (NMSC), there is limited literature on the incidence of NMSC during childhood in this population. We present 4 HSCT patients ages 13 to 20 years diagnosed with NMSC in our clinic over a 1-year period. Each patient had multiple risk factors associated with NMSC including chronic graft-versus-host disease, prolonged immunosuppression, total-body irradiation, and voriconazole therapy. We conclude that the incidence of NMSC in children after HSCT may be underestimated and should be further investigated. Appropriate skin cancer screening, including annual skin examinations, are advised for pediatric patients with identifiable risk factors.
Subject(s)
Carcinoma, Squamous Cell/epidemiology , Hematopoietic Stem Cell Transplantation , Skin Neoplasms/epidemiology , Adolescent , Adult , Antifungal Agents/administration & dosage , Boston/epidemiology , Follow-Up Studies , Graft vs Host Disease/complications , Humans , Immunocompromised Host , Incidence , Male , Neoplasm Staging , Prognosis , Pyrimidines/administration & dosage , Risk Factors , Skin Neoplasms/diagnosis , Survival Rate , Survivors , Triazoles/administration & dosage , Voriconazole , Whole-Body Irradiation , Young AdultABSTRACT
CONTEXT: Although systemic analgesic therapies are the mainstay of pain treatment in pediatric palliative care, there are cases where they fail to adequately relieve symptoms or produce side effects that undermine effectiveness. Regional anesthesia may be considered as a potential therapy for these patients. OBJECTIVES: To review the literature on regional techniques in pediatric patients with life-limiting and chronic conditions, including pain from tumor infiltration, chest pain in advanced pulmonary disease, chronic abdominal pain, phantom limb pain, and spasticity and dystonia. Where relevant, the authors' clinical experiences are included. METHODS: References were identified by searches of PubMed from 1980 until June 2012 with related terms. RESULTS: Case reports and case series were identified for each condition. Regional anesthesia techniques performed included central neuraxial infusions, peripheral nerve and plexus blocks or infusions, neurolytic blocks, and implanted intrathecal ports and pumps for baclofen, opioids, local anesthetics, and other adjuvants. The reports described positive contributions to the management of moderate-to-severe pain. Clinical context for these techniques frequently included the failure of systemic treatments and/or intolerable medication side effects. Complications varied according to the procedure and the underlying patient pathology; however, these risks were often acceptable when the potential benefits were consistent with the overall goals of care. CONCLUSION: The present medical literature on regional anesthesia techniques in children receiving palliative care is limited to case reports and case series. Based on this evidence, recommendations must be provisional. Careful thought and discussion with pain management specialists are encouraged when pain symptoms are inadequately managed or the treatments produce deleterious side effects.